Cargando…
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
After being approved by the National Drug Agency in several countries, Radium-223 (Ra-223) is gaining wide acceptance in the treatment of bone metastatic castration resistant prostate cancer. The exact mechanism of action remain unclear: The established model of direct alpha-particle irradiation fro...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084059/ https://www.ncbi.nlm.nih.gov/pubmed/27843540 http://dx.doi.org/10.4329/wjr.v8.i10.816 |